Literature DB >> 7259802

The epidemiology of giant cell arteritis including temporal arteritis and polymyalgia rheumatica. Incidences of different clinical presentations and eye complications.

B A Bengtsson, B E Malmvall.   

Abstract

During a period of three years in Göteborg, Sweden, 126 cases of giant cell arteritis (GCA) were diagnosed. Histologic evidence of arteritis was found on temporal artery biopsy in 74 (59%). The total annual incidence of GCA was calculated to be 9.3 per 100,000 inhabitants. In the age group over 50, incidence was 28.6 per 100,000. For histologically proven GCA, the incidence was 5.5 per 100,000 of the total population. The corresponding figure in the age group over 50 was 16.8 per 100,000. Twenty-six patients (21%) had a clinical presentation of temporal arteritis, and 23 (18%) had a combined picture of temporal arteritis and polymyalgia rheumatica (PMR). Sixty-seven (53%) had the PMR syndrome without any temporal symptoms, and 10 patients (8%) had a "silent" presentation with only general symptoms. The PMR syndrome was more common among women with GCA (79%) than among men (56%). The group of patients without muscular symptoms contained an equal number of men and women. Eye complications were seen in 15 patients (12%). In 6, the ocular symptoms were transient, while 9 suffered from permanent loss of vision. In 3 of these patients, temporal artery biopsy revealed no evidence of arteritis, and 5 had no clinical signs of localized temporal arteritis.

Entities:  

Mesh:

Year:  1981        PMID: 7259802     DOI: 10.1002/art.1780240706

Source DB:  PubMed          Journal:  Arthritis Rheum        ISSN: 0004-3591


  39 in total

1.  A prospective study of vasculitis patients collected in a five year period: evaluation of the Chapel Hill nomenclature.

Authors:  S F Sørensen; O Slot; N Tvede; J Petersen
Journal:  Ann Rheum Dis       Date:  2000-06       Impact factor: 19.103

Review 2.  Giant cell arteritis.

Authors:  J M Calvo-Romero
Journal:  Postgrad Med J       Date:  2003-09       Impact factor: 2.401

3.  Giant cell arteritis.

Authors:  J C Mason; M J Walport
Journal:  BMJ       Date:  1992-07-11

4.  Plasminogen activator inhibitor and von Willebrand factor in polymyalgia rheumatica.

Authors:  A Uddhammar; S Rantapåå-Dahlqvist; T K Nilsson
Journal:  Clin Rheumatol       Date:  1992-06       Impact factor: 2.980

Review 5.  Diagnosis and treatment of giant cell arteritis.

Authors:  Fabrizio Cantini; Laura Niccoli; Carlotta Nannini; Michele Bertoni; Carlo Salvarani
Journal:  Drugs Aging       Date:  2008       Impact factor: 3.923

6.  The influence of sectional interval on the reliability of temporal arterial biopsies in polymyalgia rheumatica.

Authors:  E Nordborg; C Nordborg
Journal:  Clin Rheumatol       Date:  1995-05       Impact factor: 2.980

7.  HLA antigens in polymyalgia rheumatica in northern Sweden.

Authors:  A Uddhammar; B N Sojka; S Rantapää-Dahlqvist
Journal:  Clin Rheumatol       Date:  1996-09       Impact factor: 2.980

Review 8.  Giant cell arteritis with ocular complications discovered simultaneously in two sisters.

Authors:  F Gros; J F Maillefert; A Behin; F Guignier; C Piroth; C Creuzot-Garcher; C Tavernier
Journal:  Clin Rheumatol       Date:  1998       Impact factor: 2.980

Review 9.  Giant cell arteritis. Epidemiology and treatment.

Authors:  E Nordborg; R Andersson; B A Bengtsson
Journal:  Drugs Aging       Date:  1994-02       Impact factor: 3.923

Review 10.  Polymyalgia rheumatica. Its correct diagnosis and treatment.

Authors:  F D Hart
Journal:  Drugs       Date:  1987-03       Impact factor: 9.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.